<DOC>
	<DOCNO>NCT02665832</DOCNO>
	<brief_summary>The purpose study compare safety pharmacokinetic characteristic combination amlodipine , olmesartan rosuvastatin DWJ1351 healthy male volunteer</brief_summary>
	<brief_title>Study DWJ1351 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Healthy adult male subject age 19 50 year Subjects whose body weight ≥ 55 kg Body Mass Index ( BMI ) ≥ 18.0 kg/m2 ≤ 27.0 kg/m2 Subject judge healthy suitable participation investigator base screen test result Subject provide write informed consent participate study Subject severe allergy allergic reaction amlodipine , olmesartan , rosuvastatin related drug Subject sign symptom previously diagnose disease liver , kidney , neurology , respiratory , endocrinology , hematology , cardiovascular , digestive system , reproductive system , neurology , psychology , ophthalmic skin disease Subjects serious clinical illness impact fate drug absorption Subject show vital sign number systolic blood pressure ≥150 mmHg ≤100 mmHg , number diastolic blood pressure ≥100mmHg ≤66mmHg Subject experience drug abuse Subject donate blood ( whole blood donation within last 2 month plasma donation within last 1 month ) Subject take clinical licensed medication another clinical trial within 3month period prior first administration study medication</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>